Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.
Key facts
- Who runs it
- Fondazione Italiana Linfomi - ETS
- Where
- Italy23 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 212 people enrolled
- Started
- 13 Dec 2024
- Expected to end
- Dec 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- Zanubrutinib
- Record updated
- 24 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Signed and dated informed consent form
- Waldenström's macroglobulinemia diagnosis in need of treatment according to ESMO (European Society for Medical Oncology) guideline 2018
- Patients who received Zanubrutinib according to the Italian CUP or in common practice following Zanubrutinib commercial approval
- Treatment with zanubrutinib according to current SmPC (Summary of Product Characteristics)
- Treatment decision before inclusion into this non-interventional study
- Age ≥18 years
Who cannot take part
- Patients with disease progression during a BTKi treatment (if pre-treated with BTK, only those intolerants are considered eligible)
- Contraindications according to SmPC for patients with WM
- Participation in an interventional clinical trial during zanubrutinib treatment
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a non-interventional, observational, retrospective and prospective multicenter Italian study, to describe treatment management and outcomes of Waldenström's Macroglobulinemia (WM) patients treated according to the Italian Compassionate Use Program (CUP) and receiving zanubrutinib following its commercial approval.
The 2 groups in the trial
- Retrospective cohort
All patients with Waldenström's macroglobulinemia enrolled in Pre-Reimbursement Access Program (PRAP) of Zanubrutinib, as per Compassionate Use Program (CUP) of Zanubrutinib, and patients treated with commercial drug (Brukinsa®) from PRAP closure to the study start.
- Prospective cohort
Patients with Waldenström's macroglobulinemia treated with Zanubrutinibin clinical practice enrolled from the study start up to 12 months.
Treatment: Zanubrutinib
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval
- Record updated
- 24 August 2026